Some of the pyrimidine metabolic rate–limiting enzymes, such as TK1 [45], UCK2 [46], and RRM1 [47], were reported to be associated with the poor outcomes of lung cancer in systematic review or meta-analysis. This evidence concerns the gene RRM1 and lung carcinoma.